Related references
Note: Only part of the references are listed.CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy
Alba Rodriguez-Garcia et al.
NATURE COMMUNICATIONS (2021)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Current status and future directions of cancer immunotherapy
Hongming Zhang et al.
JOURNAL OF CANCER (2018)
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine
Lainie P. Martin et al.
GYNECOLOGIC ONCOLOGY (2017)
Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis
Xia Yuan et al.
GYNECOLOGIC ONCOLOGY (2017)
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study
Kathleen N. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Affinity of human IgG subclasses to mouse Fc gamma receptors
Gillian Dekkers et al.
MABS (2017)
Complement Depletion Improves Human Red Blood Cell Reconstitution in Immunodeficient Mice
Bing Chen et al.
STEM CELL REPORTS (2017)
Phase 1 Dose-Escalation Study of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor α-Targeting Antibody-Drug Conjugate, in Patients With Solid Tumors
Kathleen N. Moore et al.
CANCER (2017)
Phase lb safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer
Kenneth H. Kim et al.
GYNECOLOGIC ONCOLOGY (2016)
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse
Ignace Vergote et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity
R. C. Lynn et al.
LEUKEMIA (2016)
Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells
Rachel C. Lynn et al.
BLOOD (2015)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors
Yasutsuna Sasaki et al.
INVESTIGATIONAL NEW DRUGS (2015)
Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer
Deborah K. Armstrong et al.
GYNECOLOGIC ONCOLOGY (2013)
Expression of M2-Polarized Macrophages is Associated with Poor Prognosis for Advanced Epithelial Ovarian Cancer
Chunyan Lan et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2013)
Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer
Colm Farrell et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer
Lana E. Kandalaft et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature
Qiong-wen Zhang et al.
PLOS ONE (2012)
Macrophages prevent human red blood cell reconstitution in immunodeficient mice
Zheng Hu et al.
BLOOD (2011)
A folate receptor beta-specific human monoclonal antibody recognizes activated macrophage of rheumatoid patients and mediates antibody-dependent cell-mediated cytotoxicity
Yang Feng et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor α, in Epithelial Ovarian Cancer: a Phase I Study
Jason A. Konner et al.
CLINICAL CANCER RESEARCH (2010)
Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor β
Taku Nagai et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Folate Receptor β Is Expressed by Tumor-Associated Macrophages and Constitutes a Marker for M2 Anti-inflammatory/Regulatory Macrophages
Amaya Puig-Kroeger et al.
CANCER RESEARCH (2009)
Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors
Kyoko Kawamura et al.
PATHOLOGY INTERNATIONAL (2009)
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
Michael H. Kershaw et al.
CLINICAL CANCER RESEARCH (2006)
Strategy for the treatment of acute myelogenous leukemia based on folate receptor β-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid
XQ Pan et al.
BLOOD (2002)
Human malaria in immunocompromised mice: New in vivo model for chemotherapy studies
A Moreno et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Human malaria in immunocompromised mice:: An in vivo model to study defense mechanisms against Plasmodium falciparum
E Badell et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
M-1/M-2 macrophages and the Th1/Th2 paradigm
CD Mills et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
